1644-71-9

Usage

Uses

Used in Pharmaceutical Industry:
5-Bromo-4-fluorosalicylic acid is used as an intermediate in the synthesis of pharmaceuticals for its ability to be incorporated into the molecular structures of various drugs. Its presence in the final products can enhance their therapeutic effects or improve their pharmacokinetic properties, such as solubility, stability, and bioavailability.
Used in Agrochemical Industry:
In the agrochemical sector, 5-Bromo-4-fluorosalicylic acid serves as a key intermediate in the production of agrochemicals, including pesticides and herbicides. Its incorporation into these compounds can enhance their efficacy in controlling pests and weeds, thereby contributing to increased crop yields and agricultural productivity.
Used in Dye Industry:
5-Bromo-4-fluorosalicylic acid is utilized in the dye industry as a precursor for the synthesis of various dyes. Its unique chemical structure allows for the creation of dyes with specific color properties, making it a valuable component in the production of textiles, paints, and other colorant applications.
Used in Materials Science:
5-Bromo-4-fluorosalicylic acid has potential applications in the field of materials science, where it can be used to develop new materials with specific properties. Its incorporation into polymers, for example, can result in materials with improved mechanical strength, thermal stability, or other desirable characteristics.
Used in Organic Chemistry Research and Development:
In the realm of organic chemistry, 5-Bromo-4-fluorosalicylic acid is employed as a reagent in various chemical reactions. Its unique structure allows for the formation of new compounds with potential applications in various industries, such as pharmaceuticals, agrochemicals, and materials science. Researchers can leverage its properties to explore new reaction pathways and develop innovative synthetic methods.
Used in Organic Building Blocks Production:
5-Bromo-4-fluorosalicylic acid is also used in the production of organic building blocks, which are essential components in the synthesis of a wide range of organic compounds. Its versatility and reactivity make it a valuable precursor for the creation of complex organic molecules with diverse applications in various industries.

InChI:InChI=1/C7H4BrFO3/c8-4-1-3(7(11)12)6(10)2-5(4)9/h1-2,10H,(H,11,12)

Upstream product

• 345-29-9 4-fluorosalicylic acid 
• 1583-58-0 2,4-difluoro-benzoic acid 

Downstream Products

• 314298-22-1 5-bromo-4-fluoro-2-methoxy-benzoic acid methyl ester 
• 1026876-50-5 5-bromo-4-fluoro-2-hydroxybenzamide 
• 927391-87-5 5-bromo-4-fluoro-2-hydroxy-3-nitrobenzoic acid 
• 1262048-06-5 benzyl 2-(benzyloxy)-5-bromo-4-fluorobenzoate 
• 4133-72-6 methyl 5-bromo-4-fluoro-2-hydroxybenzoate 

Relevant academic research and scientific papers

Identification of Novel Tricyclic Benzo[1,3]oxazinyloxazolidinones as Potent Antibacterial Agents with Excellent Pharmacokinetic Profiles against Drug-Resistant Pathogens

A series of conformationally constrained novel benzo[1,3]oxazinyloxazolidinones were designed, synthesized, and evaluated on their activities against Mycobacterium tuberculosis, Gram-positive bacteria, and Gram-negative bacteria. The studies identified a new compound 20aa that displayed good to excellent antibacterial and antitubercular profiles against drug-resistant TB strains (MIC = 0.48-0.82 μg/mL), MRSA (MIC = 0.25-0.5 μg/mL), MRSE (MIC = 1 μg/mL), VISA (MIC = 0.25 μg/mL), and VRE (MIC = 0.25 μg/mL) and some linezolid-resistant strains (MIC 1-2 μg/mL). Compound 20aa was demonstrated as a promising candidate through ADME/T evaluation including microsomal stability, cytotoxicity, and inhibition of hERG and monoamine oxidase. Notably, 20aa showed excellent mouse PK profile with high plasma exposure (AUC0-∞ = 78 669 h·ng/mL), high peak plasma concentration (Cmax = 10 253 ng/mL), appropriate half-life of 3.76 h, and superior oral bioavailability (128%). The present study not only successfully provides a novel benzo[1,3]oxazinyloxazolidinone scaffold with superior druggability but also lays a good foundation for new antibacterial drug development.

Benzo[1, 3]oxazin-oxazolidinone compounds, and preparation method and application thereof

The invention discloses benzo[1, 3]oxazin-oxazolidinone compounds, and a preparation method and application thereof, and belongs to the technical field of medicines. The invention specifically relates to application in preparation of drugs for treating an

A convenient and efficient H2SO4-promoted regioselective monobromination of phenol derivatives using N-bromosuccinimide

A convenient, rapid H2SO4-promoted regioselective monobromination reaction with N-bromosuccinimide was developed. The desired para-monobrominated or ortho-monobrominated products of phenol derivatives were obtained in good to excellent yields with high selectivity. Regioselective chlorination and iodination were also achieved in the presence of H2SO4 using N-chlorosuccinimide and N-iodosuccinimide, respectively.

INHIBITORS OF THE BCL6 BTB DOMAIN PROTEIN-PROTEIN INTERACTION AND USES THEREOF

The present application relates to compounds of Formula I (I) or pharmaceutically acceptable salts, solvates and/or prodrugs thereof, to compositions comprising these compounds or pharmaceutically acceptable salts, solvates and/or prodrugs thereof, and various uses in the treatment of diseases, disorders or conditions that are treatable by inhibiting interactions with BCL6 BTB, such as cancer.

APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS AND USES THEREOF

Described herein are ASK1 inhibitors and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for the treatment of blood disease, autoimmune disorders, pulmonary disorders, hypertension, inflammatory diseases, fibrotic diseases, diabetes, diabetic nephropathy, renal diseases, respiratory diseases, cardiovascular diseases, acute lung injuries, acute or chronic liver diseases, and neurodegenerative diseases.

Big catkin willow acids compounds and medical use

The invention discloses a AMPK agonist activity with salicylic acid compound and its preparation method and medical use, it is the structural formula of the formula (I) compound of formula, its pharmaceutically acceptable salt or prodrug or solvate. The structure of the invention of formula (I) compound of formula activated AMPK, therefore can be used for preparing the prevention or treatment of AMPK mediated diseases.

ASK1 INHIBITING AGENTS

Provided are compounds of Formulas (I'), (I), (II') and (II), or pharmaceutically acceptable salts thereof, and methods for their use and production.

METHOD FOR PRODUCING PRECURSORS FOR L-3,4-DIHYDROXY-6- [18F] FLUOROPHENYL ALAINE AND 2- [18F] FLUORO-L-TYROSINE AND THE ALPHA-METHYLATED DERIVATIVES THEREOF, PRECURSOR, AND METHOD FOR PRODUCING L-3, 4DIHYDROXY-6- [18F] FLUOROPHENYLALANINE AND 2- [18F] FLU

Disclosed is a method for producing precursors for L-3,4-dihydroxy-6-[18F]fluorophenylalanine and 2-[18F]fluoro-L-tyrosine and the α-methylated derivatives thereof, the precursor, and to a method for producing L-3,4-dihydroxy-6-[sup

Efficient synthesis of fluorobenzyloxoimidazolidinone derivatives: Precursors for the radiosynthesis of [18F]fluorophenylamino acids

This paper describes an efficient synthesis of fluorobenzyloxoimidazolidinone derivatives. The title compounds 1a, 1b and 1c could be prepared with high diasteromeric purity (>99%) and overall yields of 19%, 48% and 41% in a ten or six-step synthetic proc

Design and synthesis of highly potent and selective (2-arylcarbamoyl- phenoxy)-acetic acid inhibitors of aldose reductase for treatment of chronic diabetic complications

Recent efforts to identify treatments for chronic diabetic complications have resulted in the discovery of a novel series of highly potent and selective (2-arylcarbamoyl-phenoxy)-acetic acid aldose reductase inhibitors. The compound class features a core template that utilizes an intramolecular hydrogen bond to position the key structural elements of the pharmacophore in a conformation, which promotes a high binding affinity. The lead candidate, example 40, 5-fluoro-2-(4-bromo-2-fluoro-benzylthiocarbamoyl)-phenoxyacetic acid, inhibits aldose reductase with an IC50 of 30 nM, while being 1100 times less active against aldehyde reductase, a related enzyme involved in the detoxification of reactive aldehydes. In addition, example 40 lowers nerve sorbitol levels with an ED50 of 31 mg/kg/d po in the 4-day STZ-induced diabetic rat model.